FDA approves AstraZeneca’s Calquence for untreated mantle cell lymphoma By Investing.com
Investing.com -- AstraZeneca (LON:) in a inventory alternate submitting on Friday stated that the FDA accredited its drug Calquence (acalabrutinib) ...
Investing.com -- AstraZeneca (LON:) in a inventory alternate submitting on Friday stated that the FDA accredited its drug Calquence (acalabrutinib) ...
Copyright © 2022 - Index Investing News.
Index Investing News is not responsible for the content of external sites.